Markers of cognitive decline in PD: The case for heterogeneity

Parkinsonism and Related Disorders

Volumn 24, Issue , 2016, Pages 8-14

  Monchi, Oury ^a,b,c   Hanganu, Alexandru ^a,b   Bellec, Pierre ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CENTRE DE RECHERCHE   (Canada)

Author keywords

Biomarkers; Cognition; Dementia; Genetics; Mild cognitive impairment; Neuroimaging; Neuropsychology; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; NICOTINIC RECEPTOR ALPHA4; TAU PROTEIN;

APOE GENE; CAUSAL ATTRIBUTION; CHRNA4 GENE; DISEASE ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; MAPT GENE; MARKER GENE; MENTAL DETERIORATION; NEUROANATOMY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SNCA GENE; COGNITION DISORDERS; COMPLICATION; DIAGNOSTIC IMAGING; GENETIC HETEROGENEITY; METABOLISM; NEUROPSYCHOLOGICAL TEST;

BIOMARKERS; COGNITION DISORDERS; GENETIC HETEROGENEITY; HUMANS; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84959018380     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.01.002     Document Type: Review

References (90)

1. Bédard M.A. What is the real impact of the frontal syndrome on daily activities in Parkinson's disease without dementia?. Mental Dysfunctions in Parkinson's Disease, Monduzzi, Bologna, Italy 2004, 5-11. A.D. Korczyn (Ed.).
2. Litvan I., Goldman J.G., Tröster A.I., Schmand B.A., Weintraub D., Petersen R.C., Mollenhauer B., Adler C.H., Marder K., Williams-Gray C.H., Aarsland D., Kulisevsky J., Rodriguez-Oroz M.C., Burn D.J., Barker R.A., Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 2012, 27:349-356.
3. Broeders M., De Bie R., Velseboer D., Speelman J., Muslimovic D., Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013, 81:346-352.
4. Janvin C.C., Larsen J.P., Aarsland D., Hugdahl K. Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia. Mov. Disord. 2006, 21:1343-1349.
5. Sollinger A.B., Goldstein F.C., Lah J.J., Levey A.I., Factor S.A. Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. Park. Relat. Disord. 2010, 16:177-180.
6. Higginson C.I., Wheelock V.L., Carroll K.E., Sigvardt K.A. Recognition memory in Parkinson's disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis. J. Clin. Exp. Neuropsychol. 2005, 27:516-528.
7. Barker R.A., Williams-Gray C.H. Mild cognitive impairment and Parkinson's disease-something to remember. J. Park. Dis. 2014, 4:651-656.
8. Halliday G.M., Leverenz J.B., Schneider J.S., Adler C.H. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov. Disord. 2014, 29:634-650.
9. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., Dickson D.W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 2002, 59:102-112.
10. Harding A.J., Halliday G.M. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001, 102:355-363.
11. Adler C.H., Caviness J.N., Sabbagh M.N., Shill H.A., Connor D.J., Sue L., Evidente V.G., Driver-Dunckley E., Beach T.G. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010, 120:827-828.
12. Jellinger K.A. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010, 120:829-830.
13. Schade S., Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimer's Res. Ther. 2014, 6:72.
14. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
15. Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C., Chung K.A., Kim H., Galasko D.R., Jankovic J. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 2010, 25:2682-2685.
16. Stav A.L., Aarsland D., Johansen K.K., Hessen E., Auning E., Fladby T. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Park. Relat. Disord. 2015, 21(7):758-764.
17. Compta Y., Parkkinen L., O'Sullivan S.S., Vandrovcova J., Holton J.L., Collins C., Lashley T., Kallis C., Williams D.R., de Silva R. Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011, 134:1493-1505.
18. Williams-Gray C.H., Evans J.R., Goris A., Foltynie T., Ban M., Robbins T.W., Brayne C., Kolachana B.S., Weinberger D.R., Sawcer S.J., Barker R.A. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009, 132:2958-2969.
19. Habak C., Noreau A., Nagano-Saito A., Mejía-Constaín B., Degroot C., Strafella A.P., Chouinard S., Lafontaine A.-L., Rouleau G.A., Monchi O. Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease. Brain 2014, 137(11). 3025-2035.
20. Bohnen N.I., Albin R.L., Müller M.M., Petrou M., Kotagal V., Koeppe R.A., Scott P.J., Frey K.A. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of parkinson disease and evidence of interaction effects. JAMA Neurol. 2015, 72:194-200.
21. Hudson G., Stutt A., Eccles M., Robinson L., Allcock L.M., Wesnes K.A., Chinnery P.F., Burn D.J. Genetic variation of CHRNA4 does not modulate attention in Parkinson's disease. Neurosci. Lett. 2010, 479:123-125.
22. Huang X., Chen P., Kaufer D.I., Tröster A.I., Poole C. Apolipoprotein E and dementia in parkinson disease: a meta-analysis. Arch. Neurol. 2006, 63:189-193.
23. De Marchi F., Carecchio M., Cantello R., Comi C. Predicting cognitive decline in Parkinson's disease: can we ask the genes?. Front. Neurol. 2014, 5.
24. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B. The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
25. Somme J.H., Gomez-Esteban J.C., Molano A., Tijero B., Lezcano E., Zarranz J.J. Initial neuropsychological impairments in patients with the E46K mutation of the α-synuclein gene (PARK 1). J. Neurol. Sci. 2011, 310:86-89.
26. Fuchs J., Nilsson C., Kachergus J., Munz M., Larsson E.-M., Schüle B., Langston J., Middleton F., Ross O., Hulihan M. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922.
27. Mata I.F., Leverenz J.B., Weintraub D., Trojanowski J.Q., Chen-Plotkin A., Deerlin V.M., Ritz B., Rausch R., Factor S.A., Wood-Siverio C., Quinn J.F., Chung K.A., Peterson-Hiller A.L., Goldman J.G., Stebbins G.T., Bernard B., Espay A.J., Revilla F.J., Devoto J., Rosenthal L.S., Dawson T.M., Albert M.S., Tsuang D., Huston H., Yearout D., Hu S.C., Cholerton B.A., Montine T.J., Edwards K.L., Zabetian C.P., GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov. Disord. 2015, 10.1002/mds.26359.
28. Oeda T., Umemura A., Mori Y., Tomita S., Kohsaka M., Park K., Inoue K., Fujimura H., Hasegawa H., Sugiyama H. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol. Aging 2015, 36(12):3306-3313.
29. Christopher L., Strafella A.P. Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease. J. Neuropsychol. 2013, 7:225-240.
30. Brück A., Aalto S., Nurmi E., Bergman J., Rinne J.O. Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol. Aging 2005, 26:891-898.
31. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008, 131:1294-1302.
32. Ko J.H., Antonelli F., Monchi O., Ray N., Rusjan P., Houle S., Lang A.E., Christopher L., Strafella A.P. Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. Hum. Brain Mapp. 2013, 34:1591-1604.
33. Petrou M., Dwamena B.A., Foerster B.R., MacEachern M.P., Bohnen N.I., Müller M.L., Albin R.L., Frey K.A. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov. Disord. 2015, 30(7):928-935.
34. Gomperts S.N. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr. Neurol. Neurosci. Rep. 2014, 14:1-9.
35. Dani M., Edison P., Brooks D.J. Imaging biomarkers in tauopathies. Park. Relat. Disord. Jan 2016, 22(Suppl. 1):S26-S28.
36. Burton E.J., McKeith I.G., Burn D.J., Williams E.D., O'Brien J.T. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004, 127:791-800.
37. Abe Y., Kachi T., Kato T., Arahata Y., Yamada T., Washimi Y., Iwai K., Ito K., Yanagisawa N., Sobue G. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J. Neurol. Neurosurg. Psychiatry 2003, 74:419-422.
38. Nagamachi S., Wakamatsu H., Kiyohara S., Fujita S., Futami S., Tamura S., Nakazato M., Yamashita S., Arita H., Nishii R., Kawai K. Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy. Ann. Nucl. Med. 2008, 22:557-564.
39. Bohnen N.I., Minoshima S., Giordani B., Frey K.A., Kuhl D.E. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999, 52:541.
40. Fénelon G., Mahieux F., Huon R., Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000, 123:733-745.
41. Holroyd S., Currie L., Wooten G.F. Prospective study of hallucinations and delusions in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2001, 70:734-738.
42. Pappert E.J., Goetz C.G., Niederman F.G., Raman R., Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov. Disord. 1999, 14:117-121.
43. Sanchez-Ramos J.R., Ortoll R., Paulson G.W. VIsual hallucinations associated with parkinson disease. Arch. Neurol. 1996, 53:1265-1268.
44. Ramírez-Ruiz B., Martí M.J., Tolosa E., Giménez M., Bargalló N., Valldeoriola F., Junqué C. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur. J. Neurol. 2007, 14:750-756.
45. Hanganu A., Bedetti C., Degroot C., Mejia-Constain B., Lafontaine A.-L., Soland V., Chouinard S., Bruneau M.-A., Mellah S., Belleville S., Monchi O. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain 2014, 137:1120-1129.
46. Nagano-Saito A., Washimi Y., Arahata Y., Kachi T., Lerch J.P., Evans A.C., Dagher A., Ito K. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005, 64:224-229.
47. Laakso M.P., Partanen K., Riekkinen P., Lehtovirta M., Helkala E.-L., Hallikainen M., Hanninen T., Vainio P., Soininen H. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia. Neurology 1996, 46:678-681.
48. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 1988, 318:876-880.
49. Monchi O., Martinu K., Strafella A.P. The contribution of neuroimaging for the study of cognitive deficits in Parkinson's disease. Clin. EEG Neurosci. 2010, 41:76-81.
50. Monchi O., Petrides M., Doyon J., Postuma R.B., Worsley K., Dagher A. Neural bases of set-shifting deficits in Parkinson's disease. J. Neurosci. 2004, 24:702-710.
51. Monchi O., Petrides M., Mejia-Constain B., Strafella A.P. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 2007, 130:233-244.
52. Cools A., Van den Bercken J., Horstink M., Van Spaendonck K., Berger H. Cognitive and motor shifting aptitude disorder in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1984, 47:443-453.
53. Owen A., James M., Leigh P., Summers B., Marsden C., Quinn N., Lange K.W., Robbins T. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992, 115:1727-1751.
54. Monchi O., Petrides M., Petre V., Worsley K., Dagher A. Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging. J. Neurosci. 2001, 21:7733-7741.
55. Jubault T., Brambati S.M., Degroot C., Kullmann B., Strafella A.P., Lafontaine A.-L., Chouinard S., Monchi O. Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI. PloS one 2009, 4:e8247.
56. Nagano-Saito A., Habak C., Mejía-Constaín B., Degroot C., Monetta L., Jubault T., Bedetti C., Lafontaine A.-L., Chouinard S., Soland V. Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease. Neurobiol. Aging 2014, 35:223-231.
57. Ekman U., Eriksson J., Forsgren L., Mo S.J., Riklund K., Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 2012, 11:679-687.
58. Monchi O., Stoessl A.J. Imaging neural correlates of mild cognitive impairment in Parkinson's disease. Lancet Neurol. 2012, 11:653-655.
59. Carbon M., Reetz K., Ghilardi M.F., Dhawan V., Eidelberg D. Early Parkinson's disease: Longitudinal changes in brain activity during sequence learning. Neurobiol. Dis. 2010, 37:455-460.
60. Dagher A., Owen A.M., Boecker H., Brooks D.J. The role of the striatum and hippocampus in planning A PET activation study in Parkinson's disease. Brain 2001, 124:1020-1032.
61. Goldman-Rakic P. Cellular basis of working memory. Neuron 1995, 14:477-485.
62. Williams G.V., Goldman-Rakic P.S. Modulation of Memory Fields by Dopamine Dl Receptors in Prefrontal Cortex 1995.
63. Watanabe M., Kodama T., Hikosaka K. Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J. Neurophysiol. 1997, 78:2795-2798.
64. Cools R., Stefanova E., Barker R.A., Robbins T.W., Owen A.M. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002, 125:584-594.
65. Mattay V.S., Tessitore A., Callicott J.H., Bertolino A., Goldberg T.E., Chase T.N., Hyde T.M., Weinberger D.R. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann. Neurol. 2002, 51:156-164.
66. Tzschentke T. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol. 2001, 63:241-320.
67. Grahn J.A., Parkinson J.A., Owen A.M. The role of the basal ganglia in learning and memory: Neuropsychological studies. Behav. Brain Res. 2009, 199:53-60.
68. Agid Y., Javoy-Agid F., Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. Mov. Disord. 1987, 2:166-230.
69. Agid Y., Ruberg M., Dubois B., Pillon B. Anatomoclinical and biochemical concepts of subcortical dementia. Cognitive Neurochemistry 1987, 248-271. Oxford University Press, Oxford. S.M. Stahl, S.D. Iversen, E.C. Goodman (Eds.).
70. Martinu K., Degroot C., Madjar C., Strafella A., Monchi O. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease. Eur. J. Neurosci. 2012, 35:572-583.
71. Bannon M.J., Roth R.H. Pharmacology of mesocortical dopamine neurons. Pharmacol. Rev. 1983, 35:53-68.
72. MacDonald P.A., MacDonald A.A., Seergobin K.N., Tamjeedi R., Ganjavi H., Provost J.-S., Monchi O. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. Brain 2011, 134:1447-1463.
73. Gotham A., Brown R., Marsden C. 'Frontal'cognitive function in patients with Parkinson's disease 'on'and 'off'levodopa. Brain 1988, 111:299-321.
74. Swainson R., Rogers R., Sahakian B., Summers B., Polkey C., Robbins T. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000, 38:596-612.
75. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Enhanced or Impaired Cognitive Function in Parkinson's Disease as a Function of Dopaminergic Medication and Task Demands. Cereb. Cortex 2001, 11:1136-1143.
76. Huang C., Mattis P., Tang C., Perrine K., Carbon M., Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007, 34:714-723.
77. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 2009, 32:548-557.
78. van Eimeren T., Monchi O., Ballanger B., Strafella A.P. Dysfunction of the default mode network in Parkinson disease: a functional magnetic resonance imaging study. Arch. Neurol. 2009, 66:877.
79. Rektorova I., Krajcovicova L., Marecek R., Mikl M. Default mode network and extrastriate visual resting state network in patients with Parkinson's disease dementia. Neurodegener. Dis. 2012, 10:232-237.
80. Baggio H.-C., Segura B., Sala-Llonch R., Marti M.-J., Valldeoriola F., Compta Y., Tolosa E., Junqué C. Cognitive impairment and resting-state network connectivity in Parkinson's disease. Hum. Brain Mapp. 2015, 36:199-212.
81. Bellec P., Lavoie-Courchesne S., Dickinson P., Lerch J., Zijdenbos A., Evans A.C. The pipeline system for Octave and Matlab (PSOM): a lightweight scripting framework and execution engine for scientific workflows. Front. Neuroinform. 2012, 6:7.
82. Bellec P., Petrides M., Rosa-Neto P., Evans A. Stable group clusters in resting-state fMRI at multiple scales: from systems to regions. 16th International Conference on Functional Mapping of the Human Brain 2010.
83. Bellec P., Benhajali Y., Carbonell F., Dansereau C., Albouy G., Pelland M., Craddock C., Collignon O., Doyon J., Stip E., Orban P. Impact of the resolution of brain parcels on connectome-wide association studies in fMRI. Neuroimage 2015, S1053-8119:691-696.
84. Annanmaki T., Pohja M., Parviainen T., Hakkinen P., Murros K. Uric acid and cognition in Parkinson's disease: a follow-up study. Park. Relat. Disord. 2011, 17:333-337.
85. Bialecka M., Kurzawski M., Roszmann A., Robowski P., Sitek E.J., Honczarenko K., Gorzkowska A., Budrewicz S., Mak M., Jarosz M. Association of COMT, MTHFR, and SLC19A1 (RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenetics Genom. 2012, 22:716-724.
86. Aarsland D., Taylor J.P., Weintraub D. Psychiatric issues in cognitive impairment. Mov. Disord. 2014, 29:651-662.
87. Lin C.-H., Wu R.-M. Biomarkers of cognitive decline in Parkinson's disease. Park. Relat. Disord. 2015, 21:431-443.
88. Delenclos M., Jones D.R., McLean P.J., Uitti R.J. Biomarkers in Parkinson's disease: Advances and strategies. Park. Relat. Disord. 2016, 22:S106-S110.
89. Sauerbier A., Jenner P., Todorova A., Chaudhuri K.R. Non motor subtypes and Parkinson's disease. Park. Relat. Disord. Jan 2016, 22(Suppl. 1):S41-S46.
90. Forkert N.D., Sedlacik J., Boelmans K. Fast and fully automatic differentiation of patients with idiopathic Parkinsonian syndrome and progressive supranuclear palsy using T1-weighted MRI datasets. 22nd Annual Meeting of the Internation Society for Magnetic Resonance in Medicine. Italy, Milano 2014.